ClinicalTrials.gg
RecruitingNCT06579040HEROESUpdated Apr 15, 2026

The HEROES Trial: Hyperbaric Oxygen Therapy for Endometriosis-Related Pain

An interventional study of Monoplace Hyperbaric Chamber (Class III medical device) in Endometriosis-related Pain, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Endometriosis with a site in Canada — 12 open to participants now, 13 under way, none of them phase 3. Endometriosis · Canada.

Planned enrollment
12th of 23
64 · median 64
Started
2025
with 2 others
No phase
11 of 34
6 open now
Primary completion
2027-12
later than 10 of 12 live
Registered
31st of 34
by date

Among the 34 studies in Endometriosis with a site in Canada, this one is the 12th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 31st registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

12 of the 34 studies in Endometriosis with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Endometriosis with a site in Canada, or all of them as a file.
02

Study summary

Endometriosis, is a condition where tissue from the uterus, called endometrium, grows outside of the uterus. This effects up to 10% of women, and can lead to long-lasting, moderate to severe pelvic pain, infertility and other symptoms. This can affect a woman's quality of life (including increased risk of depression and anxiety) and is associated with increased healthcare costs.

Current treatments are often limited by serious side effects, and many women resort to surgery. Surgery is also associated with complications and there are long wait times for procedures, sometimes over 3 years. This means that many women continue to suffer from symptoms while they wait for surgery. Therefore, new effective treatments for endometriosis pain are needed.

New research suggests that inflammation and stress caused by lack of oxygen in the affected areas may cause endometriosis. Hyperbaric Oxygen Therapy (HBOT), where patients are placed in a small chamber with higher than normal levels of oxygen, suppresses inflammation and promotes tissue healing. Because inflammation is central to this condition, HBOT has emerged as a potential treatment.

In this study, the investigators will test if HBOT, in addition to the standard treatments, is more effective at treating endometriosis pain than the standard treatments alone.

Read the detailed description

Endometriosis is caused when endometrial-like tissue is found outside of the uterus. It predominantly affects women of reproductive age, with an estimated prevalence of 10% worldwide. Chronic pain related to endometriosis is one of the primary manifestations that lead individuals to seek treatment, with many women reporting moderate to severe pain that can have serious consequences for mental health and quality of life.

Current therapeutic approaches for endometriosis include hormonal therapies (e.g. oral contraceptive pills, progestins, and Gonadotropin-Releasing Hormone agonists/antagonists). While these treatments may provide temporary symptom relief, they are often associated with serious side effects and preclude conception during treatment. The efficacy of other medical interventions remains controversial, therefore surgical procedures are often indicated. However, surgery also has associated risks, has long wait times (between 6 months and 3 years), and a considerable percentage of patients experience recurrence of pain following surgical resection.

Pathologically, endometriosis is characterized by angiogenesis, inflammation, and a chronic hypoxic state at the cellular level. Because of this, Hyperbaric Oxygen Therapy (HBOT), which suppresses inflammation and promotes tissue healing, offers promise as a novel therapeutic modality. This is supported by murine models, which demonstrate the ability of HBOT to reduce inflammation and inflammatory cytokines in the context of endometriosis in animals. However, there have not been any human studies investigating the use of HBOT for treatment of endometriosis and related pain.

This study aims to explore HBOT as a treatment for endometriosis related pelvic pain. Specifically, the investigators will test if HBOT, in addition to the standard treatments (e.g. hormonal and non-hormonal medical options), is more effective at treating endometriosis pain than the standard treatments alone.

03

Conditions studied

  • Endometriosis-related Pain

Browse trials for

Keywords

  • Endometriosis
  • Endometriosis-related Pain
  • Hyperbaric Oxygen Therapy
  • HBOT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Patients having pelvic pain (NRS≥4) secondary to endometriosis for >6 months
  • May or may not be on traditional multi-modal treatment (pharmacological and/or non-pharmacological)
  • On waitlist for surgical treatment

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic pain resulting from disease processes unrelated to the pathophysiology of endometriosis-related symptoms (e.g. irritable bowel syndrome, migraine headache, fibromyalgia, chronic low back pain, and musculoskeletal injuries)
  • /medically unfit to receive hyperbaric treatments at an outpatient facility (e.g. pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)
  • Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • No intervention
    Group I (Control)

    Standard multi-modal therapy

  • Experimental
    Group II (Intervention)

    Standard multi-modal therapy + 40 HBOT treatments (2 ATM for 90 mins daily, 5 days a week)

    Device: Monoplace Hyperbaric Chamber (Class III medical device)

Interventions

  • DeviceMonoplace Hyperbaric Chamber (Class III medical device)

    Participants in the intervention group will be triaged to the closest hyperbaric facility to their address and treated with 40 HBOTs (2 ATM for 90 mins, scheduled daily from Monday to Friday). As HBOT is not a service currently offered at Sunnybrook Hospital, all HBOT treatments will be provided at three collaborating outpatient facilities, Halton Hyperbaric Unit, Restore Hyperbaric Oxygen \& Medical Centre (CPSO-certified Level-II OHP), and Rouge Valley Hyperbaric Medical Centre. All three facilities have the exact same hyperbaric chambers, run by anesthesiologists with advanced training, thus treatments will be identical at all sites.

06

What researchers measure

Primary outcomes

  1. Change in pain symptoms on the NRS

    Assessed on the numeric rating scale between 0 to 10, with 10 indicating the worst possible pain

    Time frame: At baseline, weekly for the first 8 weeks after enrollment, then at 3/4/5/6 month follow ups

Secondary outcomes

  1. Change in pain frequency

    The change in pain frequency will be assessed on a 5-point Likert scale, where 1 is "never" and 5 is "always."

    Time frame: At baseline, weekly for the first 8 weeks after enrollment, then at 3/4/5/6 month follow ups

  2. Change in opioid consumption

    Collected as a categorical variable ("Are you taking 1) more, 2) same or 3) less compared to start of treatment?")

    Time frame: At baseline, weekly for the first 8 weeks after enrollment, then at 3/4/5/6 months

  3. Participant Quality of Life on the EHP-30

    The Endometriosis Health Profile-30 is a validated, high-sensitivity, 30-item endometriosis-specific assessment tool for capturing the impact of endometriosis on patient's lives.

    Time frame: At baseline, and every month for 6 months

  4. Participant Quality of Life on the SF-36

    The Quality of Life Short Form Survey-36 is a widely used tool to assess an individual's overall health-related quality of life.

    Time frame: At baseline, and every month for 6 months

Other outcomes

  1. Adherence to HBOT protocol

    How many patients complete protocol (minimum 4 treatments per week with \>35 treatments)

    Time frame: At 8 weeks (or last session)

  2. Satisfaction assessed by a Patient Satisfaction Questionnaire

    Subjective questionnaire completion at end of treatment inquiring about HBOT experience, barriers to and promoters of treatment

    Time frame: At 8 weeks (or last session) and 6 months following enrollment

  3. Cost of study completion

    Cost of study completion on a per patient basis including research support, healthcare resource costs, and patient-related personal costs (transport, time from work)

    Time frame: Throughout study completion, an average of 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant-level data will be made available upon reasonable request to study PI following publication of full trial results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be available following publication of the full trial results.

Access criteria: Data and supporting information will be made available following reasonable request directly to study PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 32 months is above that.

Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2024
First posted
Aug 30, 2024
StartActual
Apr 8, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06579040
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Apr 8, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Fahad Alam, MD
Contact
fahad.alam@sunnybrook.ca
416-480-4864
Grace Liu, MD
Contact
grace.liu@sunnybrook.ca
416-480-6100 ext. 65063

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion